P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA
Fan Yang,
Rui Liu,
Zhonghua Fu,
Teng Xu,
Peihao Zheng,
Shaomei Feng,
Yuelu Guo,
Lixia MA,
Hui Shi,
Biping Deng,
Xiaoyan Ke,
Kai Hu
Affiliations
Fan Yang
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Rui Liu
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Zhonghua Fu
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Teng Xu
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Peihao Zheng
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Shaomei Feng
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Yuelu Guo
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Lixia MA
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Hui Shi
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Biping Deng
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Xiaoyan Ke
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
Kai Hu
1 Beijing GoBroad Boren Hospital, Department of Lymphoma and Myeloma Research Center, Beijing, China
